ClinicalTrials.gg
RecruitingNCT07684313TRIBLAZEUpdated Oct 21, 2026

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

An observational study in Heart Valve Diseases, Heart Diseases and Cardiovascular Diseases, sponsored by Edwards Lifesciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Edwards Lifesciences · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Heart Valve Diseases by Edwards Lifesciences — 3 open to participants now, 7 under way, none of them phase 3. Heart Valve Diseases · Edwards Lifesciences.

Started
2026
with 1 other
Observational
3 of 21
3 open now
Registered
20th of 21
by date

Among the 21 studies in Heart Valve Diseases by Edwards Lifesciences, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 20th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

3 of the 21 studies in Heart Valve Diseases by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Heart Valve Diseases by Edwards Lifesciences, or all of them as a file.
02

Study summary

TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.

Read the detailed description

Subjects in the TRIBLAZE study will be enrolled at up to 15 sites in the United States. The population will be participants requiring replacement of their native or prosthetic tricuspid valve.

03

Conditions studied

  • Heart Valve Diseases
  • Heart Diseases
  • Cardiovascular Diseases
  • Tricuspid Valve Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population includes adult candidates who require replacement of their native or prosthetic tricuspid valve.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Indication for TRIFORMIS valve implant for native or prosthetic valve dysfunction
  • Provide written prior to the 30-day imaging follow-up
  • Willing and able to return for scheduled follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Untreatable to nitinol alloys (nickel and titanium)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Edwards TRIFORMIS RESILIA heart valve

    Subjects who were treated with the Edwards TRIFORMIS RESILIA heart valve

    Device: Edwards TRIFORMIS RESILIA heart valve

Interventions

  • DeviceEdwards TRIFORMIS RESILIA heart valve

    Surgical replacement of the tricuspid valve with the Edwards TRIFORMIS RESILIA heart valve

06

What researchers measure

Primary outcomes

  1. Participant's average mean gradient measurement over time

    Mean gradient is the average flow of blood through the tricuspid valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

    Time frame: 1 Year

  2. Participant's average peak gradient measurement over time

    Peak gradient is the maximum value measured of flow of blood through the tricuspid valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.

    Time frame: 1 Year

  3. Participant's average Effective Orifice Area (EOA) measurement over time

    Effective orifice area represents the cross-sectional area of the blood flow downstream of the tricuspid valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.

    Time frame: 1 Year

  4. Participant's amount of tricuspid valvular regurgitation measurement over time

    Valvular regurgitation occurs when the valve in the heart does not close tightly, allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation, 1 = a trace of regurgitation, 2 = mild regurgitation, 3 = moderate regurgitation, and 4 represents severe regurgitation. Higher numbers on the scale show a worsening outcome.

    Time frame: 1 Year

  5. Participant's right ventricular function over time

    Right ventricular function is the heart's ability to pump deoxygenated blood through the pulmonary circulation into the lungs. Right ventricular function is assessed via echocardiography. It is assessed on a scale of: Normal, Mild dysfunction, Moderate dysfunction, Moderate-severe dysfunction, or Severe dysfunction.

    Time frame: 1 Year

  6. Participant's amount of paravalvular leak over time

    Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.

    Time frame: 1 Year

  7. Participant's quality of life improvement as measured on the Kansas City Cardiomyopathy Questionnaire from baseline to 1 year

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated, disease-specific health status tool for patients with heart failure. It measures symptoms, physical and social limitations, and quality of life over the previous two weeks. Scores range from 0 to 100, where higher numbers indicate better health and fewer symptoms and lower numbers indicate wore health and more symptoms.

    Time frame: Baseline and 1 Year

Secondary outcomes

  1. Participant's functional improvement over time from baseline for New York Heart Association (NYHA) Class

    The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity. Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present even at rest.

    Time frame: Baseline, 1 month, 1-, 2-, 3-, 4-, and 5- Years follow-up

  2. Percentage of participant's freedom from all cause mortality

    Participants' freedom from all cause mortality. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  3. Percentage of participant's freedom from cardiovascular mortality

    Participants' freedom from cardiovascular mortality. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  4. Percentage of participant's freedom from valve-related mortality

    Participants' freedom from valve-related mortality. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  5. Percentage of participant's freedom from tricuspid valve reintervention

    Participants' freedom from a reoperation on their tricuspid valve. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  6. Percentage of participant's freedom from valve-related pulmonary embolism

    Participants' freedom from valve-related pulmonary embolism. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  7. Percentage of participant's freedom from valve-related valve thrombosis

    Participants' freedom from valve-related valve thrombosis. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  8. Percentage of participant's freedom from valve-related hemorrhage

    Participants' freedom from valve-related hemorrhage. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  9. Percentage of participant's freedom from valve-related endocarditis

    Participants' freedom from valve-related endocarditis. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

  10. Percentage of participant's freedom from tricuspid valve-related heart failure hospitalization

    Participants' freedom from tricuspid valve-related heart failure hospitalization. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up

07

Study locations

1 of 1 sites recruiting
  • Ascension St. Vincent's Hospital
    Carmel, Indiana 46260, United States
    Recruiting
    • David Heimansohn, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be available to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2030, 47 months after the start.

Of 116 observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 212. This study's planned 47 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Sep 22, 2026was Aug 2026
Primary completionEst.
Aug 2030
CompletionEst.
Dec 2034
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
Ascension St. Vincent's Hospital is now Recruiting
Oct 21, 2026
Start date
Aug 2026→Sep 22, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    Ascension St. Vincent's Hospital is now Recruiting
    Start date Aug 2026→Sep 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684313
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Sep 22, 2026
Primary completion
Aug 2030 (estimated)
Completion
Dec 2034 (estimated)
Last update
Oct 21, 2026

Study contacts

Aya Westbrook, PhD
Contact
Aya_Westbrook@edwards.com
949-250-2500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion